Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of fenofibrate as add-on therapy for drug-resistant nocturnal frontal lobe epilepsy
2011-005433-39Phase 2Active
- Sponsor
- Azienda Ospedaliero Universitaria di Cagliari
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fenofibrate in sleep-related hypermotor epilepsy (SHE) and frontal lobe epilepsy (FLE), sponsored by Azienda Ospedaliero Universitaria di Cagliari. Primary endpoint: Clinical efficacy of fenofibrate adjunctive therapy. Started Jan 2012; status: active.
02
Drugs
fenofibrate
03
Conditions
sleep-related hypermotor epilepsy (SHE)frontal lobe epilepsy (FLE)
Beyond the preview
Go deeper on 2011-005433-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005433-39.